Robeco Institutional Asset Management B.V. Sells 9,593 Shares of Jazz Pharmaceuticals PLC (JAZZ)

Robeco Institutional Asset Management B.V. reduced its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 42.7% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 12,875 shares of the specialty pharmaceutical company’s stock after selling 9,593 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Jazz Pharmaceuticals were worth $1,594,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in JAZZ. LSV Asset Management increased its stake in Jazz Pharmaceuticals by 156.3% during the 4th quarter. LSV Asset Management now owns 764,460 shares of the specialty pharmaceutical company’s stock worth $94,762,000 after buying an additional 466,168 shares during the period. Scout Investments Inc. purchased a new stake in Jazz Pharmaceuticals during the 4th quarter worth approximately $54,686,000. AQR Capital Management LLC increased its stake in Jazz Pharmaceuticals by 156.6% during the 3rd quarter. AQR Capital Management LLC now owns 344,313 shares of the specialty pharmaceutical company’s stock worth $57,889,000 after buying an additional 210,156 shares during the period. Bank of New York Mellon Corp increased its stake in Jazz Pharmaceuticals by 14.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,690,385 shares of the specialty pharmaceutical company’s stock worth $284,205,000 after buying an additional 207,954 shares during the period. Finally, Boston Partners increased its stake in Jazz Pharmaceuticals by 17.8% during the 4th quarter. Boston Partners now owns 1,315,371 shares of the specialty pharmaceutical company’s stock worth $163,054,000 after buying an additional 198,306 shares during the period. 91.97% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:JAZZ opened at $135.70 on Thursday. Jazz Pharmaceuticals PLC has a 52 week low of $113.52 and a 52 week high of $184.00. The company has a current ratio of 4.29, a quick ratio of 4.16 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $8.20 billion, a price-to-earnings ratio of 11.09, a PEG ratio of 0.88 and a beta of 1.17.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, February 26th. The specialty pharmaceutical company reported $3.64 EPS for the quarter, beating the Zacks’ consensus estimate of $2.66 by $0.98. Jazz Pharmaceuticals had a net margin of 28.09% and a return on equity of 24.92%. The company had revenue of $476.46 million for the quarter, compared to the consensus estimate of $459.48 million. During the same period in the prior year, the firm posted $2.95 EPS. The company’s quarterly revenue was up 9.2% compared to the same quarter last year. On average, research analysts forecast that Jazz Pharmaceuticals PLC will post 13.35 earnings per share for the current year.

Several equities research analysts recently weighed in on the stock. BidaskClub raised shares of Jazz Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, January 7th. Cantor Fitzgerald set a $185.00 target price on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, February 26th. Morgan Stanley set a $168.00 target price on shares of Jazz Pharmaceuticals and gave the stock a “hold” rating in a research note on Wednesday, November 28th. Zacks Investment Research reaffirmed a “hold” rating on shares of Jazz Pharmaceuticals in a research note on Tuesday, November 13th. Finally, Mizuho cut their target price on shares of Jazz Pharmaceuticals to $157.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 20th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have given a buy rating to the company. Jazz Pharmaceuticals has an average rating of “Buy” and a consensus price target of $190.63.

In other Jazz Pharmaceuticals news, CFO Matthew P. Young sold 1,916 shares of the stock in a transaction that occurred on Wednesday, February 27th. The shares were sold at an average price of $131.46, for a total value of $251,877.36. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Paul Treacy sold 874 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $139.50, for a total transaction of $121,923.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 12,790 shares of company stock worth $1,774,501. Insiders own 3.90% of the company’s stock.

WARNING: This piece was first published by Markets Daily and is the property of of Markets Daily. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.themarketsdaily.com/2019/03/07/robeco-institutional-asset-management-b-v-sells-9593-shares-of-jazz-pharmaceuticals-plc-jazz.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Featured Article: Fiduciary

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.